Kalvista Pharmaceuticals Stock Alpha and Beta Analysis
| KALV Stock | USD 15.75 0.09 0.57% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Kalvista Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Kalvista Pharmaceuticals over a specified time horizon. Remember, high Kalvista Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Kalvista Pharmaceuticals' market risk premium analysis include:
Beta 1.66 | Alpha 0.38 | Risk 4.16 | Sharpe Ratio 0.13 | Expected Return 0.56 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Check out Kalvista Pharmaceuticals Backtesting, Kalvista Pharmaceuticals Valuation, Kalvista Pharmaceuticals Correlation, Kalvista Pharmaceuticals Hype Analysis, Kalvista Pharmaceuticals Volatility, Kalvista Pharmaceuticals History and analyze Kalvista Pharmaceuticals Performance. Kalvista Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Kalvista Pharmaceuticals market risk premium is the additional return an investor will receive from holding Kalvista Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Kalvista Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Kalvista Pharmaceuticals' performance over market.| α | 0.38 | β | 1.66 |
Kalvista Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Kalvista Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Kalvista Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Kalvista Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Kalvista Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Kalvista Pharmaceuticals shares will generate the highest return on investment. By understating and applying Kalvista Pharmaceuticals stock market price indicators, traders can identify Kalvista Pharmaceuticals position entry and exit signals to maximize returns.
| Price Series Summation | ||
| Price Series Division | ||
| Inverse Tangent Over Price Movement | ||
| Price Ceiling Movement | ||
| Aroon Oscillator | ||
| Balance Of Power | ||
| Parabolic SAR | ||
| MidPoint over period | ||
| Stalled Pattern | ||
| Separating Lines |
Kalvista Pharmaceuticals Return and Market Media
The median price of Kalvista Pharmaceuticals for the period between Thu, Oct 9, 2025 and Wed, Jan 7, 2026 is 13.34 with a coefficient of variation of 16.08. The daily time series for the period is distributed with a sample standard deviation of 2.15, arithmetic mean of 13.37, and mean deviation of 1.92. The Stock received some media coverage during the period. Price Growth (%) |
| Timeline |
1 | How sentiment analysis helps forecast KalVista Pharmaceuticals Inc. - Short Setup Accurate Technical Buy Alerts - newser.com | 10/16/2025 |
2 | Acquisition by Benjamin Palleiko of 9364 shares of Kalvista Pharmaceuticals subject to Rule 16b-3 | 11/04/2025 |
3 | Citizens Touts KalVista Pharmaceuticals, Inc. Growth Trajectory on EKTERLY Prospects | 11/18/2025 |
4 | Disposition of 87390 shares by Christopher Yea of Kalvista Pharmaceuticals at 0.0043 subject to Rule 16b-3 | 11/20/2025 |
5 | Disposition of 5000 shares by Audhya Paul K. of Kalvista Pharmaceuticals subject to Rule 16b-3 | 11/21/2025 |
6 | Disposition of 10940 shares by Benjamin Palleiko of Kalvista Pharmaceuticals at 13.451 subject to Rule 16b-3 | 11/24/2025 |
7 | Positive Outlook for KalVista Pharmaceuticals Amid Competitive Developments and Market Growth Potential - TipRanks | 12/03/2025 |
8 | Disposition of 6250 shares by Nicole Sweeny of Kalvista Pharmaceuticals subject to Rule 16b-3 | 12/04/2025 |
9 | Disposition of 15625 shares by Benjamin Palleiko of Kalvista Pharmaceuticals subject to Rule 16b-3 | 12/05/2025 |
10 | Disposition of 7294 shares by Benjamin Palleiko of Kalvista Pharmaceuticals at 16.51 subject to Rule 16b-3 | 12/08/2025 |
11 | KalVista Pharmaceuticals Reaches New 1-Year High - Heres Why - MarketBeat | 12/15/2025 |
12 | KalVista Pharmaceuticals Announces Approval of EKTERLY in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema | 12/22/2025 |
13 | Acquisition by Audhya Paul K. of 5000 shares of Kalvista Pharmaceuticals subject to Rule 16b-3 | 12/23/2025 |
14 | KalVista Upgraded as 2026 Top Idea De-Risked Competitive Landscape, Strengthening Launch Trajectory, and Raised 32 Target Support Buy Rating - TipRanks | 01/06/2026 |
About Kalvista Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Kalvista or other stocks. Alpha measures the amount that position in Kalvista Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Kalvista Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Kalvista Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Kalvista Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Kalvista Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Kalvista Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Kalvista Pharmaceuticals' management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 5th of July 2024 Next Financial Report | View | |
| 31st of January 2024 Next Fiscal Quarter End | View | |
| 5th of July 2024 Next Fiscal Year End | View | |
| 31st of October 2023 Last Quarter Report | View | |
| 30th of April 2023 Last Financial Announcement | View |
Build Portfolio with Kalvista Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Kalvista Stock Analysis
When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.